Volume | 1,188,097 |
|
|||||
News | - | ||||||
Day High | 0.42 | Low High |
|||||
Day Low | 0.37 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Theriva Biologics Inc | TOVX | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.42 | 0.37 | 0.42 | 0.3769 | 0.411 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,273 | 1,188,097 | $ 0.3880816 | $ 461,079 | - | 0.1972 - 1.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
20:00:00 | 138 | $ 0.3769 | USD |
Theriva Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.31M | 17.04M | - | 0 | -18.35M | -1.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Theriva Biologics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TOVX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4309 | 0.45 | 0.37 | 0.4127044 | 252,032 | -0.0538 | -12.49% |
1 Month | 0.505 | 0.505 | 0.37 | 0.4266191 | 102,566 | -0.1279 | -25.33% |
3 Months | 0.4418 | 0.6845 | 0.37 | 0.5136471 | 119,794 | -0.0647 | -14.64% |
6 Months | 0.443 | 0.6845 | 0.1972 | 0.49808 | 86,184 | -0.0659 | -14.88% |
1 Year | 0.6591 | 1.20 | 0.1972 | 0.8180832 | 236,769 | -0.282 | -42.79% |
3 Years | 0.80 | 1.26 | 0.1972 | 0.8098725 | 178,798 | -0.4229 | -52.86% |
5 Years | 0.80 | 1.26 | 0.1972 | 0.8098725 | 178,798 | -0.4229 | -52.86% |
Theriva Biologics Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. |